Commentary
The aim of this study by R. Loomba et al. (NAFLD Research Center, University of California, San Diego, USA) was to evaluate the impact of disease severity, demographics and comorbidities on risk of mortality and time to progression in a large, real-world cohort of diagnosed NAFLD patients.
In a randomly selected, generalisable sample of Medicare patients, the authors report herein findings of the need for improved real-world clinical practice identification of NAFLD/NASH and a high clinical burden associated with diagnosed NAFLD/NASH patients in the Medicare population, including substantial risk of mortality and liver disease progression.
